Look Below the Surface

With Molecular Testing

View FAQs

IMPORTANT UPDATE

Interpace Diagnostics® Continues to Offer PancraGEN® and Fluid Chemistry Testing

The Genetic Testing for Oncology LCD (L39365), posted for notice on June 2, 2023 by Novitas Solutions, Inc., will not become effective on July 17, 2023.

As a result, Interpace Diagnostics® is able to continue offering PancraGEN® and the related Point2® fluid chemistry tests for amylase, CEA, and glucose.

We thank our valued customers for your strong support of our testing services. We encourage you to continue sharing your perspectives on the importance and value of PancraGEN with Novitas Solutions, Inc.

PancraGEN and Point2 Fluid Chemistry Tests for Amylase, CEA and Glucose Continue to be Available

Questions regarding this update or relating to PancraGEN and the Point2 fluid chemistry tests can be addressed by contacting Interpace Client Services.

(800) 495-9655 or clientservices@interpace.com

IDX-0042-03-0723

Limitations and Disclaimers1
Although PancraGEN is highly specific for malignancy, some malignant cysts may not be detected. There may also be individuals who are falsely identified as having a malignant cyst. Diagnosis and appropriate patient management are the responsibility of the referring physician or healthcare provider.

Reference 1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-142. 

Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2023 Interpace Biosciences, Inc.™ All rights reserved.
Privacy Policy | HIPAA Privacy

Scroll to Top